Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Intralesional therapy for metastatic melanoma
Sarah Sloot, Omar M. Rashid, Jonathan S. Zager
Expert Opinion on Pharmacotherapy (2014) Vol. 15, Iss. 18, pp. 2629-2639
Closed Access | Times Cited: 19

Showing 19 citing articles:

Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants
Sachin Bhagchandani, Jeremiah A. Johnson, Darrell J. Irvine
Advanced Drug Delivery Reviews (2021) Vol. 175, pp. 113803-113803
Open Access | Times Cited: 126
Intratumoral Immunotherapy—Update 2019
Omid Hamid, Rubina Ismail, Igor Puzanov
The Oncologist (2019) Vol. 25, Iss. 3, pp. e423-e438
Open Access | Times Cited: 135
Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1–derived oncolytic immunotherapy
Kevin J. Harrington, Igor Puzanov, J. Randolph Hecht, et al.
Expert Review of Anticancer Therapy (2015) Vol. 15, Iss. 12, pp. 1389-1403
Open Access | Times Cited: 116
Natural products from aquatic eukaryotic microorganisms for cancer therapy: Perspectives on anti-tumour properties of ciliate bioactive molecules
Elisabetta Catalani, Francesca Proietti Serafini, Silvia Zecchini, et al.
Pharmacological Research (2016) Vol. 113, pp. 409-420
Closed Access | Times Cited: 46
Climacostol reduces tumour progression in a mouse model of melanoma via the p53-dependent intrinsic apoptotic programme
Cristiana Perrotta, Federico Buonanno, Silvia Zecchini, et al.
Scientific Reports (2016) Vol. 6, Iss. 1
Open Access | Times Cited: 42
Developments in Intralesional Therapy for Metastatic Melanoma
Sarah Sloot, Omar M. Rashid, Amod A. Sarnaik, et al.
Cancer Control (2016) Vol. 23, Iss. 1, pp. 12-20
Open Access | Times Cited: 42
A practical guide to the handling and administration of talimogene laherparepvec in Europe
Kevin J. Harrington, Olivier Michielin, Josep Malvehy, et al.
OncoTargets and Therapy (2017) Vol. Volume 10, pp. 3867-3880
Open Access | Times Cited: 41
The Role of Regional Therapies for in-Transit Melanoma in the Era of Improved Systemic Options
Emmanuel Gabriel, Joseph J. Skitzki
Cancers (2015) Vol. 7, Iss. 3, pp. 1154-1177
Open Access | Times Cited: 24
Surgical Management of Melanoma
Kenneth M. Joyce
Codon Publications eBooks (2017), pp. 91-100
Open Access | Times Cited: 19
The Evolution and Future of Targeted Cancer Therapy: From Nanoparticles, Oncolytic Viruses, and Oncolytic Bacteria to the Treatment of Solid Tumors
Kyle M. Pierce, William R. Miklavcic, Kyle P. Cook, et al.
Nanomaterials (2021) Vol. 11, Iss. 11, pp. 3018-3018
Open Access | Times Cited: 15
Intralesional immunotherapy as a strategy to treat melanoma
Noura Nouri, Claus Garbe
Expert Opinion on Biological Therapy (2016) Vol. 16, Iss. 5, pp. 619-626
Closed Access | Times Cited: 16
Rose Bengal: The Second Most Commonly Used Surfocular Vital Stain
Juan Murube
The Ocular Surface (2013) Vol. 12, Iss. 1, pp. 14-22
Closed Access | Times Cited: 11
Case Report: Combined Intra-Lesional IL-2 and Topical Imiquimod Safely and Effectively Clears Multi-Focal, High Grade Cutaneous Squamous Cell Cancer in a Combined Liver and Kidney Transplant Patient
Dejan Vidovic, Gordon A. Simms, Sylvia Pasternak, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 10
Pharmacokinetic drug evaluation of talimogene laherparepvec for the treatment of advanced melanoma
Erin E. Burke, Jonathan S. Zager
Expert Opinion on Drug Metabolism & Toxicology (2018) Vol. 14, Iss. 4, pp. 469-473
Closed Access | Times Cited: 9
Talimogene Laherparepvec: Overview, Combination Therapy and Current Practices
Cristina O’Donoghue, Matthew P. Doepker, Jonathan S. Zager
Melanoma Management (2016) Vol. 3, Iss. 4, pp. 267-272
Open Access | Times Cited: 7
Intratumoral immunotherapy with anti-PD-1 and TLR9 agonist induces systemic antitumor immunity without accelerating rejection of cardiac allografts
Nana Dang, Mark Waer, Ben Sprangers, et al.
American Journal of Transplantation (2020) Vol. 21, Iss. 1, pp. 60-72
Open Access | Times Cited: 6
Early Events of the Reaction Elicited by CSF-470 Melanoma Vaccine Plus Adjuvants: An In Vitro Analysis of Immune Recruitment and Cytokine Release
M. Betina Pampena, María Marcela Barrio, Estefanía P. Juliá, et al.
Frontiers in Immunology (2017) Vol. 8
Open Access | Times Cited: 4
Treatment of Locoregional Recurrences of Skin Melanoma (a Clinical Case)
О. Н. Ганусевич, Т. Н. Нестерович, И. В. Федоркевич, et al.
Kuban Scientific Medical Bulletin (2020) Vol. 27, Iss. 3, pp. 105-112
Open Access
New intratumoral immunotherapeutic approaches to inhibit the tumor growth and metastasis in breast cancer
Carmen T. Gómez de León, Jorge Morales‐Montor
Elsevier eBooks (2021), pp. 33-46
Closed Access
Page 1

Scroll to top